BPA for ferriprox, revcovi

Ended Awarded Last action

Contract number
36E79721A0020
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Last date to order 100% complete
IDV ceiling
$2,250,000.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

This Blanket Purchase Agreement, awarded by the VA's National Acquisition Center on September 10, 2021, establishes a single-award, non-set-aside vehicle with a ceiling value of $2.25 million for the procurement of two specialty pharmaceutical products: Ferriprox (deferiprone) and Revcovi (luspatercept). Prime contractor Chiesi USA Inc., a specialty pharmaceutical company, will supply these critical medications to the Department of Veterans Affairs through the contract's completion on September 9, 2026. The BPA references 2026 Public Law pricing updates, indicating that pharmaceutical pricing may be subject to statutory adjustments during the performance period. As the underlying master contract is the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), task orders and delivery orders issued against this BPA will leverage the established GSA Schedule pricing and terms while allowing the VA to efficiently procure these iron chelation and anemia treatment medications for distribution across Veterans Health Administration networks.

Ferriprox and Revcovi are specialized pharmaceutical products used to treat iron overload and anemia in patient populations, conditions prevalent among veterans requiring ongoing pharmaceutical management. The VA's establishment of this blanket purchase agreement streamlines the acquisition process for these therapies by consolidating procurement through a single vendor and pricing structure, thereby reducing administrative burden while ensuring reliable supply chain access to critical medications. Historical delivery orders indicate distribution to multiple Veterans Integrated Service Networks (VISNs), including VISN 5, VISN 12, VISN 17, and VISN 22, demonstrating the nationwide scope of veteran healthcare support facilitated through this IDV vehicle.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00019 · 2026 public law pricing updates. $0
Supplemental Agreement for work within scope P00017 · This modification is issued to incorporate the product additions of 4 juxtapid ndcs and 1 elfabrio NDC to BPA 36E79721A0020, along with the deletion of 1… $0
Exercise an Option P00018 · This modification is issued to exercise option year 4 on BPA 36E79721A0020. $0
Supplemental Agreement for work within scope P00016 · This modification is issued to incorporate the product additions of 4 juxtapid ndcs and 1 elfabrio NDC to BPA 36E79721A0020, along with the deletion of 1… $0
Supplemental Agreement for work within scope P00014 · This modification is issued to delete 2 bronchitol ndcs from BPA 36E79721A0020. $0
Supplemental Agreement for work within scope P00015 · This modification is issued to incorporate 2025 public law pricing updates into BPA 36E79721A0020. $0
Supplemental Agreement for work within scope P00013 · This modification is issued to incorporate a price increase to 3 ndcs on BPA 36E79721A0020. $0
Exercise an Option P00012 · This modification is issued to exercise option year 3 on BPA 36E79721A0020. $0
Supplemental Agreement for work within scope P00011 · This modification is issued to incorporate the product additions of 4 juxtapid ndcs and 1 myalept NDC to BPA 36E79721A0020. $0
Supplemental Agreement for work within scope P00010 · 2024 public law pricing updates $0
Supplemental Agreement for work within scope P00009 · Addition of elfabrico (3 line items) to BPA. $0
Exercise an Option P00008 · Modification to exercise option year 2 on BPA 36E79721A0020. The period of performance is 09/10/2023 - 09/09/2024. $0
Supplemental Agreement for work within scope P00007 · Lamzede and ferriprox product additions $0
Supplemental Agreement for work within scope P00006 · 2023 public law pricing updates $0
Supplemental Agreement for work within scope P00005 · Addition of two bronchitol ndcs (10122-0212-56 and 10122-0212-04) $0
Exercise an Option P00004 · Exercise option year 1 on BPA 36E79721A0020 $0
Supplemental Agreement for work within scope P00003 · Deletion of two ferriprox and one revcovi NDC, and incorporate one revcovi NDC change into BPA 36E79721A0020. $0
Supplemental Agreement for work within scope P00002 · 2022 public law pricing updates $0
Supplemental Agreement for work within scope P00001 · Deletion of one ferriprox NDC, incorporate two ferriprox NDC changes into BPA 36E79721A0020. $0
Original award $0
Show all 20

Quick answers

Who was awarded contract 36E79721A0020?

36E79721A0020 was awarded to Chiesi USA Inc. by National Acquisition Center (Headquarters) on September 10, 2021.

How much is contract 36E79721A0020 worth?

36E79721A0020's own ceiling is $2,250,000.

Who can order from contract 36E79721A0020?

36E79721A0020 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79721A0020 under another contract?

Yes. 36E79721A0020 is a blanket purchase agreement under 36F79720D0214, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79721A0020 competed?

The extent of competition for 36E79721A0020 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV